A neural‐related gene risk score for head and neck squamous cell carcinoma

• Published in: Oral diseases Vol. 30; no. 2; pp. 477 - 491
• Main Authors: Tao, Zhuo‐ying, Yang, Wei‐fa, Zhu, Wang‐yong, Wang, Lei‐lei, Li, Kar Yan, Guan, Xin‐yuan, Su, Yu‐xiong
• Format: Journal Article
• Language: English
• Published: Denmark Wiley Subscription Services, Inc 01.03.2024
• Subjects: CD4 antigen; Gene expression; Genes; Genomes; Head & neck cancer; head and neck cancer; Head and neck carcinoma; Immune checkpoint inhibitors; Immunotherapy; Lymphocytes T; Macrophages; Mast cells; Medical prognosis; Metastases; nerve‐cancer crosstalk; overall survival; prognostic signature; Squamous cell carcinoma; Survival analysis; Transcriptomes; overall survival; nerve-cancer crosstalk; head and neck cancer; immunotherapy; prognostic signature
• ISSN: 1354-523X; 1601-0825
• DOI: 10.1111/odi.14434

Objectives This study aimed to establish a neural‐related gene risk score (NRGRS) for the prediction of head and neck squamous cell carcinoma prognosis and explore its predictive value on the benefit of immune checkpoint inhibitor therapy. Methods Based on the transcriptome data of HNSCC patients (n = 546) from The Cancer Genome Atlas database, 37 neural‐related hub genes were identified by weighted gene co‐expression network analysis. Four genes (ITGA5, PYGM, GNG7 and ATP2A3) were identified to construct NRGRS using Lasso‐Cox regression method based on the derivation cohort and validated in the Gene Expression Omnibus cohort (n = 109). The survival analysis was performed to validate the prognostic value of NRGRS and immune characteristics in NRGRS‐defined subgroups were analyzed. Results NRGRS‐high patients had a worse overall survival than NRGRS‐low patients. Tumors with high NRGRS were more likely to have high infiltration of naive CD4+ T cells, M0, M2 macrophages and resting mast cells, which illustrated suppressive immunity and less benefit from immunotherapy therapy. Conclusion NRGRS strongly correlates with survival and is a promising biomarker to predict immunotherapy benefits for head and neck cancer patients. This study provides evidence for the potential correlation between neural‐related transcriptome alteration and immune activity.